Francesca Crisafulli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Francesca Crisafulli has a total of 404 co-authors. Here are the top co-authors by number of shared publications:
- Angela Tincani
Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, ERN-ReCONNET Center, 25123 Brescia, Italy
12 shared publications - Laura Andreoli
University of Brescia
10 shared publications - Franco Franceschini
Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy
9 shared publications - Maria Grazia Lazzaroni
Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
9 shared publications - Cecilia Nalli
Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, ERN-ReCONNET Center, 25123 Brescia, Italy
6 shared publications Franco Franceschini
Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
5 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (7)
Development and validation of a Relapsing Polychondritis disease-specific Quality of Life instrument (ERN ReCONNET RP-QoL)
Objectives: Relapsing polychondritis (RP) is a rare, multisystem inflammatory disease characterized by heterogeneous clinical manifestations and a substantial impact on patients’ daily functioning and well-being. Health-related quality of life (HR-QoL) in RP remains insufficiently characterized, and no disease-specific measurement tool is available so far. This study aimed to develop and validate the RP-QoL, a multilingual, patient-reported outcome instrument specifically designed to assess HR-QoL in individuals with RP. Methods: The RP-QoL was developed within the European Reference Network ReCONNET using a structured four-step approach: (1) identification of relevant HR-QoL domains through systematic literature review, an international patient survey, and expert consensus; (2) item generation; (3) pilot testing including cognitive debriefing; and (4) comprehensive psychometric validation. Validation analyses included assessment of internal consistency, structural validity, construct validity, convergent validity with the SF-36, and criterion-related validity. Results: Domain identification incorporated input from 274 patients across 22 countries, leading to a 31-item pilot questionnaire with a 28-day recall period and 5-point response scale. Cognitive debriefing confirmed clarity, relevance, and feasibility. Validation in 239 patients from 19 countries (median age 55 years; 80% female) demonstrated excellent internal consistency (Cronbach’s α = 0.96). Exploratory factor analysis supported near-unidimensionality, with the first factor explaining 46.6% of variance. RP-QoL scores correlated strongly with disease impact (ρ = −0.62, p< 0.0001) and SF-36 physical (ρ = 0.65) and mental (ρ = 0.55, p< 0.0001) components (both p< 0.0001, p< 0.0001). Discriminative ability was high (AUC = 0.87). Conclusion: The RP-QoL is the first validated, disease-specific HR-QoL instrument for RP, with robust psychometric performance and applicability in both clinical practice and research.
- 1 July 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (7)
Open AccessDevelopment and validation of a Relapsing Polychondritis disease-specific Quality of Life instrument (ERN ReCONNET RP-QoL)
Objectives: Relapsing polychondritis (RP) is a rare, multisystem inflammatory disease characterized by heterogeneous clinical manifestations and a substantial impact on patients’ daily functioning and well-being. Health-related quality of life (HR-QoL) in RP remains insufficiently characterized, and no disease-specific measurement tool is available so far. This study aimed to develop and validate the RP-QoL, a multilingual, patient-reported outcome instrument specifically designed to assess HR-QoL in individuals with RP. Methods: The RP-QoL was developed within the European Reference Network ReCONNET using a structured four-step approach: (1) identification of relevant HR-QoL domains through systematic literature review, an international patient survey, and expert consensus; (2) item generation; (3) pilot testing including cognitive debriefing; and (4) comprehensive psychometric validation. Validation analyses included assessment of internal consistency, structural validity, construct validity, convergent validity with the SF-36, and criterion-related validity. Results: Domain identification incorporated input from 274 patients across 22 countries, leading to a 31-item pilot questionnaire with a 28-day recall period and 5-point response scale. Cognitive debriefing confirmed clarity, relevance, and feasibility. Validation in 239 patients from 19 countries (median age 55 years; 80% female) demonstrated excellent internal consistency (Cronbach’s α = 0.96). Exploratory factor analysis supported near-unidimensionality, with the first factor explaining 46.6% of variance. RP-QoL scores correlated strongly with disease impact (ρ = −0.62, p< 0.0001) and SF-36 physical (ρ = 0.65) and mental (ρ = 0.55, p< 0.0001) components (both p< 0.0001, p< 0.0001). Discriminative ability was high (AUC = 0.87). Conclusion: The RP-QoL is the first validated, disease-specific HR-QoL instrument for RP, with robust psychometric performance and applicability in both clinical practice and research.
- Open Access
- 29 April 2026
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (11) , 1691-1700
Assessing the Sensitivity and the Clinical Impact of the 2023 American College of Rheumatology/ EULAR Classification Criteria in Obstetric Antiphospholid Syndrome: Findings From a Multicenter Italian Cohort With a Long‐Term Follow‐Up
Objective: The aim of this study was to evaluate the sensitivity of the 2023 American College of Rheumatology (ACR)/EULAR classification criteria for antiphospholipid syndrome (APS) in a real‐world cohort of women diagnosed with primary obstetric APS (oAPS) and to assess their ability to identify patients at risk of future pregnancy complications. Methods: We conducted a multicenter retrospective study on women diagnosed with primary oAPS by expert rheumatologists between 2006 and 2023 in two Italian rheumatology centers. All patients were retrospectively classified using both the 2006 Sydney and the 2023 ACR/EULAR classification criteria. Follow‐up at one and five years after clinical diagnosis was analyzed to identify new obstetric events and assess associations with baseline classification status. Results: Our cohort included 122 women. At baseline, 75.4% of patients fulfilled the Sydney criteria and 23% met the 2023 ACR/EULAR criteria. The main reasons for exclusion under the 2023 ACR/EULAR criteria were insufficient clinical score due to isolated fetal losses (56.4%), insufficient laboratory score due to isolated IgM antiphospholipid antibody positivity (4.3%), or a combination of both (5.3%). During five years of follow‐up, more than one‐quarter of the patients who became pregnant experienced new obstetric events. The majority of these patients did not fulfill the 2023 ACR/EULAR criteria. Conclusion: The 2023 ACR/EULAR classification criteria demonstrate low sensitivity (23%) in women with primary oAPS and fail to identify those at risk of future events. These findings underscore the need for cautious clinical judgment in managing oAPS: misuse of these criteria may result in undertreatment and increase the risk of recurrent obstetric complications.
- 29 April 2026
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (11) , 1691-1700
Open AccessAssessing the Sensitivity and the Clinical Impact of the 2023 American College of Rheumatology/ EULAR Classification Criteria in Obstetric Antiphospholid Syndrome: Findings From a Multicenter Italian Cohort With a Long‐Term Follow‐Up
Objective: The aim of this study was to evaluate the sensitivity of the 2023 American College of Rheumatology (ACR)/EULAR classification criteria for antiphospholipid syndrome (APS) in a real‐world cohort of women diagnosed with primary obstetric APS (oAPS) and to assess their ability to identify patients at risk of future pregnancy complications. Methods: We conducted a multicenter retrospective study on women diagnosed with primary oAPS by expert rheumatologists between 2006 and 2023 in two Italian rheumatology centers. All patients were retrospectively classified using both the 2006 Sydney and the 2023 ACR/EULAR classification criteria. Follow‐up at one and five years after clinical diagnosis was analyzed to identify new obstetric events and assess associations with baseline classification status. Results: Our cohort included 122 women. At baseline, 75.4% of patients fulfilled the Sydney criteria and 23% met the 2023 ACR/EULAR criteria. The main reasons for exclusion under the 2023 ACR/EULAR criteria were insufficient clinical score due to isolated fetal losses (56.4%), insufficient laboratory score due to isolated IgM antiphospholipid antibody positivity (4.3%), or a combination of both (5.3%). During five years of follow‐up, more than one‐quarter of the patients who became pregnant experienced new obstetric events. The majority of these patients did not fulfill the 2023 ACR/EULAR criteria. Conclusion: The 2023 ACR/EULAR classification criteria demonstrate low sensitivity (23%) in women with primary oAPS and fail to identify those at risk of future events. These findings underscore the need for cautious clinical judgment in managing oAPS: misuse of these criteria may result in undertreatment and increase the risk of recurrent obstetric complications.
- Open Access
- 8 April 2026
- Published by MDPI AG in Antibodies
- Vol. 15 (2) , 32
Monoclonal Antibodies in Pregnancy of Patients with Systemic Lupus Erythematosus: Friend or Foe? A Case Report of a Patient with Multiple Pregnancies
Systemic lupus erythematosus (SLE) is an autoimmune disease that predominantly affects women of childbearing age, and active disease during pregnancy is associated with increased maternal and fetal morbidity. Belimumab is an effective biologic therapy for active SLE; however, its use during pregnancy has long been limited by the scarcity of safety data. Recent evidence and updated international recommendations suggest that belimumab may be considered in selected cases when required to maintain maternal disease control. We report the case of a woman with SLE who experienced three consecutive pregnancies with live births between 2019 and 2024 while receiving belimumab, allowing an intra-individual comparison of different exposure strategies. During the first pregnancy, belimumab was discontinued at conception and was followed by a disease flare in late pregnancy and postpartum. In the second and third pregnancies, belimumab was continued until gestational week 20 following shared decision-making with the patient; nevertheless, disease flares occurred during the third trimester of both pregnancies. All pregnancies resulted in live births at term, with no congenital anomalies, placental insufficiency, or fetal growth restriction. One neonate from the third pregnancy developed early-onset neonatal sepsis and meningitis, which resolved completely after antibiotic treatment. All children are currently growing and developing normally. This case supports a risk-adapted approach to belimumab use during pregnancy. In selected women with SLE at high risk of disease reactivation, continuation of belimumab until mid-gestation may contribute to improved maternal disease control without evident adverse fetal outcomes.
- 8 April 2026
- Published by MDPI AG in Antibodies
- Vol. 15 (2) , 32
Open AccessMonoclonal Antibodies in Pregnancy of Patients with Systemic Lupus Erythematosus: Friend or Foe? A Case Report of a Patient with Multiple Pregnancies
Systemic lupus erythematosus (SLE) is an autoimmune disease that predominantly affects women of childbearing age, and active disease during pregnancy is associated with increased maternal and fetal morbidity. Belimumab is an effective biologic therapy for active SLE; however, its use during pregnancy has long been limited by the scarcity of safety data. Recent evidence and updated international recommendations suggest that belimumab may be considered in selected cases when required to maintain maternal disease control. We report the case of a woman with SLE who experienced three consecutive pregnancies with live births between 2019 and 2024 while receiving belimumab, allowing an intra-individual comparison of different exposure strategies. During the first pregnancy, belimumab was discontinued at conception and was followed by a disease flare in late pregnancy and postpartum. In the second and third pregnancies, belimumab was continued until gestational week 20 following shared decision-making with the patient; nevertheless, disease flares occurred during the third trimester of both pregnancies. All pregnancies resulted in live births at term, with no congenital anomalies, placental insufficiency, or fetal growth restriction. One neonate from the third pregnancy developed early-onset neonatal sepsis and meningitis, which resolved completely after antibiotic treatment. All children are currently growing and developing normally. This case supports a risk-adapted approach to belimumab use during pregnancy. In selected women with SLE at high risk of disease reactivation, continuation of belimumab until mid-gestation may contribute to improved maternal disease control without evident adverse fetal outcomes.
- 30 March 2026
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
AA amyloidosis as a rare presentation leading to the diagnosis of mevalonate kinase deficiency in a male adult: a diagnostic challenge mimicking familial Mediterranean fever
Letters to the Editor; Authors: A.C. Pozzi, G. Voltarel, P. Airo', M. Frassi, I. Cavazzana, F. Crisafulli
- 30 March 2026
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
AA amyloidosis as a rare presentation leading to the diagnosis of mevalonate kinase deficiency in a male adult: a diagnostic challenge mimicking familial Mediterranean fever
Letters to the Editor; Authors: A.C. Pozzi, G. Voltarel, P. Airo', M. Frassi, I. Cavazzana, F. Crisafulli
- 27 February 2026
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Assessment of long-term organ damage and predictors of damage accrual in Behçet's syndrome: a 10-year longitudinal study using the Behçet's Syndrome Overall Damage Index
Full Papers; Authors: G. Voltarel, A.-C. Pozzi, P. Airò, A. Melzani, M. Frassi, I. Cavazzana, F. Crisafulli
- 27 February 2026
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Assessment of long-term organ damage and predictors of damage accrual in Behçet's syndrome: a 10-year longitudinal study using the Behçet's Syndrome Overall Damage Index
Full Papers; Authors: G. Voltarel, A.-C. Pozzi, P. Airò, A. Melzani, M. Frassi, I. Cavazzana, F. Crisafulli
- 19 November 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Risk of major organ involvement in Behçet’s patients with mucocutaneous onset: data from the AIDA Network Registry
Objectives: The progression of Behçet’s disease (BD) from a mucocutaneous-limited form to major organ involvement (MOI) represents a significant challenge. This study aims to identify patients without MOI at BD onset who are at increased risk of developing MOI in later stages. Methods: Patients’ data were drawn from the International AutoInflammatory Disease Alliance (AIDA) Network registry dedicated to BD. Results: A total of 328 patients with exclusively mucocutaneous manifestations at BD onset were enrolled. Of these, 82 patients (25%) developed MOI over the entire follow-up period. Patients with minor oral aphthosis and no major oral aphthosis exhibited a reduced risk of developing MOI, with an odds ratio (OR) of 0.41 [95% confidence interval (95%CI): 0.22–0.79, P = 0.008]. Conversely, patients with both major and minor oral aphthosis had a significantly higher risk of developing MOI, with an OR of 12.76 (95%CI: 1.44–113, P = 0.02). Moreover, the development of MOI was associated with major oral aphthosis plus genital aphthosis (OR: 2.49, 95%CI: 1.1–5.6, P = 0.03), major oral aphthosis plus pseudofolliculitis (OR: 2.9, 95%CI: 1.15–7.4, P = 0.02) and major oral aphthosis plus both genital aphthosis and pseudofolliculitis (OR: 3.73, 95%CI: 1.22–11.4, P = 0.02). A positive family history for BD was associated with MOI (OR: 2.85, 95%CI: 1.08–7.58, P = 0.03). Conclusion: A positive family history and the presence of major oral aphthosis combined with minor oral aphthosis, genital aphthosis or pseudofolliculitis are associated with MOI development in patients with mucocutaneous BD at onset.
- 19 November 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Risk of major organ involvement in Behçet’s patients with mucocutaneous onset: data from the AIDA Network Registry
Objectives: The progression of Behçet’s disease (BD) from a mucocutaneous-limited form to major organ involvement (MOI) represents a significant challenge. This study aims to identify patients without MOI at BD onset who are at increased risk of developing MOI in later stages. Methods: Patients’ data were drawn from the International AutoInflammatory Disease Alliance (AIDA) Network registry dedicated to BD. Results: A total of 328 patients with exclusively mucocutaneous manifestations at BD onset were enrolled. Of these, 82 patients (25%) developed MOI over the entire follow-up period. Patients with minor oral aphthosis and no major oral aphthosis exhibited a reduced risk of developing MOI, with an odds ratio (OR) of 0.41 [95% confidence interval (95%CI): 0.22–0.79, P = 0.008]. Conversely, patients with both major and minor oral aphthosis had a significantly higher risk of developing MOI, with an OR of 12.76 (95%CI: 1.44–113, P = 0.02). Moreover, the development of MOI was associated with major oral aphthosis plus genital aphthosis (OR: 2.49, 95%CI: 1.1–5.6, P = 0.03), major oral aphthosis plus pseudofolliculitis (OR: 2.9, 95%CI: 1.15–7.4, P = 0.02) and major oral aphthosis plus both genital aphthosis and pseudofolliculitis (OR: 3.73, 95%CI: 1.22–11.4, P = 0.02). A positive family history for BD was associated with MOI (OR: 2.85, 95%CI: 1.08–7.58, P = 0.03). Conclusion: A positive family history and the presence of major oral aphthosis combined with minor oral aphthosis, genital aphthosis or pseudofolliculitis are associated with MOI development in patients with mucocutaneous BD at onset.
- Open Access
- 30 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Unfolding dermatological spectrum of Still’s disease: a cohort study from the International AIDA Network Still’s Disease Registry
Objectives: To investigate cutaneous manifestations in Still’s disease patients, evaluating any correlation with ethnic origin, age at disease onset, disease patterns, occurrence of macrophage activation syndrome (MAS) and systemic activity scores. Methods: Data were retrospectively drawn from the International AutoInflammatory Disease Alliance (AIDA) Network Registry dedicated to Still’s disease. Results: A total of 518 patients (41.3% males) were enrolled. Salmon-coloured evanescent skin rash (n = 304, 63.9%), macules (n = 40, 7.7%), urticarial eruptions (n = 31, 5.9%), erythema (n = 27, 5.2%) and persistent pruritic papules and plaques (PPPP) (n = 25, 4.8%) accounted for the most frequent skin manifestations observed in Still’s disease. Overall, atypical skin rash were described in 110 (21.2%) patients. Salmon-coloured evanescent skin rash and pruritus were more common among patients aged <16 years compared with patients aged 16–60 (P = 0.002 and P = 0.008, respectively). Pruritus was significantly more frequent among White than among Arab patients (P = 0.008) and in polycyclic vs monocyclic course (P = 0.049). Hispanics showed a significantly higher rate of atypical skin manifestations compared with Arabs (P = 0.036) and White (P = 0.036). Also, macules were more frequent among Hispanics than White (P = 0.027), while PPPP was more frequent among Hispanics than Arabs (P = 0.023) and White (P = 0.002). Salmon-coloured evanescent skin rash was significantly more frequent among patients with a systemic activity score ≥7 (P < 0.001). Conclusion: The present study enhances dermatologists’ awareness of the diverse cutaneous lesions that may represent heterogeneous manifestations of Still’s disease, shedding new light on the difference related to the age at disease onset, the patients’ ethnic origin and the severity of the disease.
- 30 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Open AccessUnfolding dermatological spectrum of Still’s disease: a cohort study from the International AIDA Network Still’s Disease Registry
Objectives: To investigate cutaneous manifestations in Still’s disease patients, evaluating any correlation with ethnic origin, age at disease onset, disease patterns, occurrence of macrophage activation syndrome (MAS) and systemic activity scores. Methods: Data were retrospectively drawn from the International AutoInflammatory Disease Alliance (AIDA) Network Registry dedicated to Still’s disease. Results: A total of 518 patients (41.3% males) were enrolled. Salmon-coloured evanescent skin rash (n = 304, 63.9%), macules (n = 40, 7.7%), urticarial eruptions (n = 31, 5.9%), erythema (n = 27, 5.2%) and persistent pruritic papules and plaques (PPPP) (n = 25, 4.8%) accounted for the most frequent skin manifestations observed in Still’s disease. Overall, atypical skin rash were described in 110 (21.2%) patients. Salmon-coloured evanescent skin rash and pruritus were more common among patients aged <16 years compared with patients aged 16–60 (P = 0.002 and P = 0.008, respectively). Pruritus was significantly more frequent among White than among Arab patients (P = 0.008) and in polycyclic vs monocyclic course (P = 0.049). Hispanics showed a significantly higher rate of atypical skin manifestations compared with Arabs (P = 0.036) and White (P = 0.036). Also, macules were more frequent among Hispanics than White (P = 0.027), while PPPP was more frequent among Hispanics than Arabs (P = 0.023) and White (P = 0.002). Salmon-coloured evanescent skin rash was significantly more frequent among patients with a systemic activity score ≥7 (P < 0.001). Conclusion: The present study enhances dermatologists’ awareness of the diverse cutaneous lesions that may represent heterogeneous manifestations of Still’s disease, shedding new light on the difference related to the age at disease onset, the patients’ ethnic origin and the severity of the disease.
- Top Cited PapersOpen Access
- 11 August 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 509-522
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel
Objective: Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality. Methods: Given the variability in disease presentation and the limited number of studies to date, no clinical documents currently exist to provide guidance to health care providers about the management of VEXAS. To address this gap, we formed an international multidisciplinary panel of VEXAS experts. Results: Through formalized meetings and a voting process, the group developed consensus clinical guidance considerations for the management of VEXAS. These considerations offer practical advice on several key topics: (1) clinical features of VEXAS, (2) UBA1 screening methods, (3) the diagnosis of myelodysplastic syndromes (MDSs) in patients with VEXAS, and (4) prognosis and management. The aim is to provide expert guidance on which patients to test, how to test for VEXAS, how to approach MDS in the context of VEXAS, and considerations for management. Conclusion: This work marks the first formal international consensus guidance for VEXAS and is intended to be used as a resource for clinicians seeking to understand the disease and its management.
- 11 August 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 509-522
Top Cited PapersOpen AccessAmerican College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel
Objective: Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality. Methods: Given the variability in disease presentation and the limited number of studies to date, no clinical documents currently exist to provide guidance to health care providers about the management of VEXAS. To address this gap, we formed an international multidisciplinary panel of VEXAS experts. Results: Through formalized meetings and a voting process, the group developed consensus clinical guidance considerations for the management of VEXAS. These considerations offer practical advice on several key topics: (1) clinical features of VEXAS, (2) UBA1 screening methods, (3) the diagnosis of myelodysplastic syndromes (MDSs) in patients with VEXAS, and (4) prognosis and management. The aim is to provide expert guidance on which patients to test, how to test for VEXAS, how to approach MDS in the context of VEXAS, and considerations for management. Conclusion: This work marks the first formal international consensus guidance for VEXAS and is intended to be used as a resource for clinicians seeking to understand the disease and its management.
- Open Access
- 29 July 2025
- Published by PAGEPress Publications in Reumatismo
- Vol. 77 (4)
The use of tumor necrosis factor inhibitors during high-risk pregnancies in antiphospholipid syndrome: a clinical report of a patient with concomitant Takayasu arteritis and case-based review
In the field of obstetric antiphospholipid syndrome (APS), studies in mouse models and case reports support the potential benefit of tumor necrosis factor-α inhibitors (TNF-α-i ) in preventing pregnancy loss associated with APS. We present the case of a 36-year-old woman with a diagnosis of Takayasu arteritis who suffered from antiphospholipid antibody (aPL)-related thrombotic microangiopathy/probable catastrophic APS during her first pregnancy and who had a subsequent successful pregnancy while on treatment with certolizumab pegol (CZP), heparin, and low-dose aspirin. The report is followed by the literature review of published cases of APS or aPL-positive pregnancies treated with CZP or other TNF-α-i . A total of 20 pregnancies, including the one here presented, were reported in high-risk APS patients exposed to TNF-α-i , showing a favorable outcome in most pregnancies (80% live births, 69% absence of adverse pregnancy outcomes). Despite the limited available evidence, TNF-α-i could represent a promising option for high-risk patients in obstetric APS.
- 29 July 2025
- Published by PAGEPress Publications in Reumatismo
- Vol. 77 (4)
Open AccessThe use of tumor necrosis factor inhibitors during high-risk pregnancies in antiphospholipid syndrome: a clinical report of a patient with concomitant Takayasu arteritis and case-based review
In the field of obstetric antiphospholipid syndrome (APS), studies in mouse models and case reports support the potential benefit of tumor necrosis factor-α inhibitors (TNF-α-i ) in preventing pregnancy loss associated with APS. We present the case of a 36-year-old woman with a diagnosis of Takayasu arteritis who suffered from antiphospholipid antibody (aPL)-related thrombotic microangiopathy/probable catastrophic APS during her first pregnancy and who had a subsequent successful pregnancy while on treatment with certolizumab pegol (CZP), heparin, and low-dose aspirin. The report is followed by the literature review of published cases of APS or aPL-positive pregnancies treated with CZP or other TNF-α-i . A total of 20 pregnancies, including the one here presented, were reported in high-risk APS patients exposed to TNF-α-i , showing a favorable outcome in most pregnancies (80% live births, 69% absence of adverse pregnancy outcomes). Despite the limited available evidence, TNF-α-i could represent a promising option for high-risk patients in obstetric APS.
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 30 (7S) , S49-S55
Reproductive Health in Scleroderma, Vasculitis, and Sjögren Syndrome
Women with systemic chronic inflammatory disease, such as those with scleroderma, systemic vasculitis, and Sjögren syndrome, need preconception evaluation by a multidisciplinary team. Counseling and pregnancy management should be tailored to patients' needs, considering specific disease features, organ involvement, treatment options, and risk factors to minimize risks of maternal-fetal complications during pregnancy. Additionally, considerations regarding fertility, assisted reproductive techniques, and contraception also need to be addressed for these women. In this narrative review, we integrate the current published literature with our expert opinion to address the issues faced by patients with the aforementioned inflammatory conditions.
- 1 October 2024
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 30 (7S) , S49-S55
Open AccessReproductive Health in Scleroderma, Vasculitis, and Sjögren Syndrome
Women with systemic chronic inflammatory disease, such as those with scleroderma, systemic vasculitis, and Sjögren syndrome, need preconception evaluation by a multidisciplinary team. Counseling and pregnancy management should be tailored to patients' needs, considering specific disease features, organ involvement, treatment options, and risk factors to minimize risks of maternal-fetal complications during pregnancy. Additionally, considerations regarding fertility, assisted reproductive techniques, and contraception also need to be addressed for these women. In this narrative review, we integrate the current published literature with our expert opinion to address the issues faced by patients with the aforementioned inflammatory conditions.